Recently, Fluence hosted a webinar featuring Taylor West, Executive Director of the Healing Advocacy Fund, to discuss the evolving legislative landscape surrounding psychedelic therapy. For practitioners considering how to position themselves in this emerging field, whether through state-regulated programs or future FDA-approved pathways, the conversation offered a crucial perspective on what's coming, what's already here, and how to prepare.
The State of State Programs: New Mexico and Beyond
One of the most pressing questions practitioners have right now concerns state-level psychedelic therapy programs. Unlike what many assume, these programs aren't fully formed overnight. Take New Mexico, for example. While legislation has been passed to establish a psilocybin therapy program, the actual infrastructure remains under development. The law created the framework - the "bones," as West describes it - but much of the detailed implementation remains to be determined.
This distinction matters enormously for therapists. If you're considering practicing psilocybin facilitation in New Mexico or watching developments there, understand that many operational rules haven't been finalized yet. The Healing Advocacy Fund is actively involved in helping the state design this program, with hopes for rollout by year's end. This ongoing development is actually an opportunity: practitioners who stay informed during the implementation phase can better understand the landscape as it crystallizes.
For those in Colorado, the lessons learned there are already informing newer programs. And for practitioners in other states considering similar pathways, the pattern being established across these state-regulated programs offers a roadmap.
State Programs vs. FDA Approval: Complementary Pathways
A natural question emerges when considering psychedelic therapy's future: How do state-regulated programs relate to potential FDA approval of psychedelic medicines? Are they competing models, or can they coexist?
According to West, these pathways are complementary rather than contradictory. State programs set important precedents for how psychedelic-assisted therapy might function in a post-FDA environment. Here's a critical distinction: state-level programs can prioritize what West calls a "wraparound care model,” robust psychotherapeutic support surrounding the medicine session itself, in ways that FDA approval processes might not emphasize to the same degree.
This matters because psilocybin-assisted therapy fundamentally differs from traditional pharmaceuticals. It's not simply "condition + drug = cure." The therapeutic relationship and psychotherapeutic support are essential to long-term, lasting benefits. State programs can design their regulatory structures around this reality from the ground up. FDA processes, operating within their own approval frameworks, may not prioritize these wraparound elements to the same extent.
The takeaway? Both pathways will likely exist, and understanding how they differ helps practitioners anticipate what professional preparation might look like under each scenario.
Medicine-Specific Considerations: One Size Doesn't Fit All
An often-overlooked point in discussions about psychedelic therapy: not all medicines operate identically, nor should they be regulated identically.
Psilocybin has an excellent safety profile, the primary safety considerations involve setting and environment rather than acute physiological concerns. Other medicines require different risk-mitigation strategies. Ibogaine, for instance, has cardiovascular implications that demand specific program design considerations. MDMA presents different session dynamics than psilocybin. Rather than lumping all psychedelic medicines under one regulatory umbrella, thoughtful program design acknowledges these differences.
For practitioners, this suggests future training and credentialing may become increasingly medicine-specific. Your preparation for psilocybin facilitation may differ from preparation for ketamine-assisted psychotherapy or other emerging modalities. This specificity isn't a barrier, it's evidence-based practice.
Practical Business Realities for New Practitioners
Beyond policy and legislation, West offered frank advice for practitioners launching practices: the financial runway is longer than many expect.
Building a sustainable psilocybin therapy practice takes time. You won't immediately maintain sufficient client volume to sustain yourself through psilocybin work alone. This isn't pessimism, it's realistic planning. Colorado's program structure, refined based on Oregon's experiences, increasingly encourages practitioners to offer psilocybin therapy as part of a broader service menu. Why? From a capacity standpoint, conducting multiple intensive psilocybin therapy sessions weekly is emotionally and logistically demanding. Practitioners who integrate other therapeutic services can maintain their emotional bandwidth while diversifying revenue streams.
This isn't secondary work; it's strategic sustainability. Mixing psilocybin facilitation with other services means you're not entirely dependent on your ability to manage numerous deep-work sessions each week. You can maintain quality care while ensuring your practice survives its early years.
Building Community as You Build Practice
An underutilized resource mentioned in the discussion: the Fluence Google group (available to all Fluence alumni) and similar practitioner networks. As state programs roll out and regulations remain fluid, having access to other practitioners navigating similar challenges, whether geographically proximate or working with similar modalities, becomes invaluable. These communities offer recommendations, collaboration opportunities, and practical problem-solving approaches that accelerate your learning curve.
Beginning Your Journey: The Essential First Step
If you're reading this and considering how to prepare for psychedelic-assisted therapy practice, whether targeting Colorado's program, watching New Mexico's development, or positioning yourself for future opportunities, the first step remains the same.
Fluence's Essentials of Psychedelic Therapy course serves as the foundational course for all our certificate programs, including psilocybin facilitation training. A session begins April 21st, and enrollment is currently open.
This course isn't just coursework; it's your entry point into understanding the theoretical, practical, and ethical foundations of psychedelic-assisted therapy. As state programs continue rolling out and the field evolves, starting with a solid educational foundation ensures you're building on evidence-based understanding rather than assumptions.
Whether you're interested in psilocybin facilitation, ketamine-assisted psychotherapy, or our psychedelic harm reduction & integration training, we have programs addressing diverse practitioner needs and client-centered care approaches.
Have questions about which course path aligns with your goals? Feel free to reach out or schedule an info call. The landscape is shifting rapidly, but your preparation can begin today.
